As data management partner, ICON will use its data management capabilities, and understanding of the growing role genomics data will have in clinical trials, to validate clinical data from the 70,000 participating patients and their families.
ICON announced that it has been selected by Genomics England as its data management partner for the 100,000 Genomes Project.
Announced by the British Prime Minister in 2012, the 100,0000 Genomes Project is sequencing 100,000 whole genomes from 70,000 National Health Service (NHS) cancer and rare disease patients and their families. De-identified data from the Project will be made available to approved researchers from industry to help accelerate the development of new treatments and diagnostic tests that are targeted at the genetic characteristics of individual patients.
As Genomics England’s data management partner, ICON will use its data management capabilities, and understanding of the growing role genomics data will have in clinical trials, to validate clinical data from the 70,000 participating patients and their families. This work will take place within the secure Genomics England data environment.
Read the full release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.